We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pfizer will offer its prescription medications to the estimated 43 million Americans without insurance at significant discounts or for free, the company announced yesterday.
Drugmakers’ wholesale prices for nearly 200 brand Rx drugs most commonly used by seniors increased far faster than the rate of inflation for the first three months of 2004, according to a study released yesterday by the AARP.
Generic firms are in position to launch versions of Abbott Laboratories’ profitable antibiotic Biaxin once the basic patent expires next May, but expected legal moves by Abbott could delay generic entry, experts say.
Wyeth has announced it will change warning labeling on its antidepressant, Effexor and Effexor XR to reflect possible complications to neonates exposed to the product during the third trimester of pregnancy.
Generic firms were cleared to market versions of several widely used levothyroxine sodium thyroid products after the FDA turned down a citizen petition that argued additional bioequivalency studies were required for approval.
Barr Pharmaceuticals has been ordered to pay $68 million to Solvay Pharmaceuticals as part of an arbitration panel ruling that found Barr’s subsidiary Duramed Pharmaceuticals improperly ended a contract to co-promote products with Solvay.
Multiple generic firms have launched versions of Bristol-Myers Squibb’s (BMS’) Type 2 diabetes drug Glucophage XR, 500-mg strength tablets, under a “second tier” of 180-day marketing exclusivity.
The FDA has issued an approvable letter for Pfizer’s new drug application for Cardura XL, a sustained-release formulation of doxazosin mesylate that will be marketed by generic firm Andrx.
Existing biotech brand firms, rather than traditional generic drugmakers, likely will be the first to go after the nearly $10 billion worth of biologic products going off patent in the next few years, experts say.